England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

Terminal patients could get years more with their loved ones as the NHS offers Blenrep, which can put some blood cancer ...

A “TROJAN HORSE” therapy that sneaks toxic drugs inside and kills cancer cells is being rolled out on the NHS in England in a ...

NHS England has confirmed that it will be the first health system worldwide to roll out the treatment. The drug will be ...

England becomes the first country to offer the world’s pioneering 'Trojan horse' blood cancer drug, through NHS, promising ...

The National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending GSK’s Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) for ...

NHS England said that it is the first health system in the world to roll out the treatment. Officials said that the drug can ...

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone.

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of GSK’s Blenrep (belantamab mafodotin) for treating the adult population with relapsed or refractory multiple ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for Blenrep (belantamab mafodotin) for the treatment of relapsed or ...